Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Oxaliplatin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 35,910Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer angles Braftovi combo for full FDA approval
    Pfizer angles Braftovi combo for full FDA approval

    04 Feb 2025

    // PRESS RELEASE

    https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-combination-regimen-significantly

    PRESS RELEASE
    04 Feb 2025
    Share Share
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg
    Oxaliplatin Europe Offers EU GMP Approved Cancer Drug Mfg

    27 Jul 2024

    // PRESS RELEASE

    https://www.naprodgroup.com/propofol_europe.php

    PRESS RELEASE
    27 Jul 2024
    Share Share
    Roche's Columvi Extends Large B-Cell Lymphoma Survival
    Roche's Columvi Extends Large B-Cell Lymphoma Survival

    15 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/15/2899263/0/en/Roche-s-Phase-III-STARGLO-study-demonstrates-Columvi-significantly-extends-survival-in-people-with-relapsed-or-refractory-diffuse-large-B-cell-lymphoma.html

    GLOBENEWSWIRE
    15 Jun 2024
    Share Share
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
    Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

    14 Feb 2024

    // PRESS RELEASE

    https://investors.merrimack.com/news-releases/news-release-details/merrimack-reports-ipsen-announcement-approval-us-fda-onivyder

    PRESS RELEASE
    14 Feb 2024
    Share Share
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer
    FDA approves Taiho's Lonsurf with bevacizumab for metastatic colorectal cancer

    03 Aug 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-approves-taihos-lonsurf-with-bevacizumab-for-third-line-metastatic-colorectal-cancer/

    Zachary Brennan ENDPTS
    03 Aug 2023
    Share Share
    FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer
    FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer

    01 Jul 2023

    // ONCLIVE

    https://www.onclive.com/view/folfox-produces-varying-toxicity-profile-vs-chemoradiation-in-rectal-cancer

    ONCLIVE
    01 Jul 2023
    Share Share